<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title></title></head><body><div><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by Professor James W Ironside</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> CBE FRSE</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">(CJD0001)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Executive Summary</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Considerable uncertainties exist about the </span><span style="font-family:'Times New Roman'; font-size:11pt">likely future numbers of clinical vCJD cases and the </span><span style="font-family:'Times New Roman'; font-size:11pt">prevalence of subclinical (asymptomatic) vCJD infection in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt">, particularly in the elderly.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Tissue-based studies indicate that </span><span style="font-family:'Times New Roman'; font-size:11pt">the</span><span style="font-family:'Times New Roman'; font-size:11pt"> prevalence of </span><span style="font-family:'Times New Roman'; font-size:11pt">subclinical vCJD is </span><span style="font-family:'Times New Roman'; font-size:11pt">around 1 in 2000 individuals in the</span><span style="font-family:'Times New Roman'; font-size:11pt"> UK</span><span style="font-family:'Times New Roman'; font-size:11pt">, but more needs to be done to determine the specificity of the methodology employed</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">vCJD infection has been transmitted from subclinically infected individuals by red blood cell transfusion and also likely by UK-derived clotting factors</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">All definite cases of vCJD have occurred in the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 </span><span style="font-family:'Times New Roman'; font-size:11pt">MM genetic subgroup – the other subgroups (MV and VV) appear to be capable of being infected, but no definite clinical cases have emerged yet.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The incubation period of vCJD in the MV and VV </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> genetic subgroups is uncertain, but could extend to several decades.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">An effective UK surveillance system</span><span style="font-family:'Times New Roman'; font-size:11pt"> is critical for the monitoring </span><span style="font-family:'Times New Roman'; font-size:11pt">of vCJD in the UK and will allow the early identification of any changes in the frequen</span><span style="font-family:'Times New Roman'; font-size:11pt">cy and character of the disease and address the questions over the prevalence of clinical vCJD in the elderly.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The wide range of measures to limit the secondary spread of vCJD in healthcare settings and measures to prevent the re-emergence of BSE in ruminants should be maintained.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">International collaboration is required to develop blood tests and meaningful clinical trials for all forms of CJD, including subclinical vCJD. </span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Background to my re</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">search on human prion diseases </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">that is relevant to the questions </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">that</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> I have been invited to </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">respond</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> to for this Evidence Session</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">I am Professor of Clinical Neuropathology in the University of Edinburgh and Honorary Consultant Neuropathologist in NHS Lothian Hospitals Division. I have worked in the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK </span><span style="font-family:'Times New Roman'; font-size:11pt">National CJD </span><span style="font-family:'Times New Roman'; font-size:11pt">Surveillance Unit (now renamed as </span><span style="font-family:'Times New Roman'; font-size:11pt">t</span><span style="font-family:'Times New Roman'; font-size:11pt">he National CJD Research &amp; Surveillance Unit (NCJDRSU)) since it was established by the Department of Health in 1990 in the University of Edinburgh. The key aim</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> of NCJDRSU </span><span style="font-family:'Times New Roman'; font-size:11pt">are</span><span style="font-family:'Times New Roman'; font-size:11pt"> to </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">monitor the characteristics of all forms of CJD, to identify trends in incidence rates, to study risk factors for the development of disease and to contribute to improving the quality of care for those with CJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> (</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; font-weight:normal; text-decoration:underline">www.cjd.ed.ac.uk</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">)</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">In 1996, my colleagues and I identified a new form of Creutzfeldt-Jakob disease (CJD) that </span><span style="font-family:'Times New Roman'; font-size:11pt">is known as variant CJD (vCJD)</span><span style="font-family:'Times New Roman'; font-size:11pt"> (28</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">, and in collaboration with other researchers we demonstrated that the infectious agent or prion causing vCJD (but not </span><span style="font-family:'Times New Roman'; font-size:11pt">sporadic CJD (sCJD), the commonest form of CJD</span><span style="font-family:'Times New Roman'; font-size:11pt">) closely resembled the prion causing bovine spongiform encephalopathy (BSE)</span><span style="font-family:'Times New Roman'; font-size:11pt"> in its biochemical profile on Western blot assay </span><span style="font-family:'Times New Roman'; font-size:11pt">(5) </span><span style="font-family:'Times New Roman'; font-size:11pt">and on experimental transmission in a strain typing assay</span><span style="font-family:'Times New Roman'; font-size:11pt"> (3)</span><span style="font-family:'Times New Roman'; font-size:11pt">. On the basis of this finding, vCJD is often referred to as “the human form of BSE”. Since then, my colleagues and I have monitored the incidence of vCJD in the UK and studied in detail the clinical and neuropathological features of the disease</span><span style="font-family:'Times New Roman'; font-size:11pt"> (11,16)</span><span style="font-family:'Times New Roman'; font-size:11pt">. We also undertook </span><span style="font-family:'Times New Roman'; font-size:11pt">epidemiological studies and </span><span style="font-family:'Times New Roman'; font-size:11pt">a case control study (funded by DH)</span><span style="font-family:'Times New Roman'; font-size:11pt"> (27</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> to identify risk factors for vCJD, and produced a set of </span><span style="font-family:'Times New Roman'; font-size:11pt">diagnostic criteria that was accepted by the World Health Organisation (WHO)</span><span style="font-family:'Times New Roman'; font-size:11pt"> (30</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">; NCJDRSU is now both a national and international referral centre for cases of suspected vCJD. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The NCJDRSU </span><span style="font-family:'Times New Roman'; font-size:11pt">website (</span><a href="http://www.cjd.ed.ac.uk"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">www.cjd.ed.ac.uk</span></a><span style="font-family:'Times New Roman'; font-size:11pt">) </span><span style="font-family:'Times New Roman'; font-size:11pt">gives updated information on all forms of CJD in the UK and has figures for all the vCJD cases in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> (current total 177 cases)</span><span style="font-family:'Times New Roman'; font-size:11pt">, including data on the incidence and death rates from this disease</span><span style="font-family:'Times New Roman'; font-size:11pt">, both of which show a decline in recent years</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Most cases of vCJD occur in young adults with a median age at death of 28 years; the age at death has not changed greatly </span><span style="font-family:'Times New Roman'; font-size:11pt">over time</span><span style="font-family:'Times New Roman'; font-size:11pt">. Only 5 cases of vCJD have been identified in patients aged 60 years and over. </span><span style="font-family:'Times New Roman'; font-size:11pt">All definite cases of vCJD (that have been confirmed pathologically) belong to a genetic subgroup of the population defined by a </span><span style="font-family:'Times New Roman'; font-size:11pt">naturally occurring</span><span style="font-family:'Times New Roman'; font-size:11pt"> polymorphism at codon 129 in the open reading frame of the prion protein gene </span><span style="font-family:'Times New Roman'; font-size:11pt">(</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt">) </span><span style="font-family:'Times New Roman'; font-size:11pt">on chromosome 22. Either methionine (M) or valine (V) can be encoded, resulting in 3 possible genotypes: MM, MV and VV</span><span style="font-family:'Times New Roman'; font-size:11pt"> (Table 1)</span><span style="font-family:'Times New Roman'; font-size:11pt">. All definite vCJD cases possess the MM genotype. There is evidence that the MV and VV genotypes </span><span style="font-family:'Times New Roman'; font-size:11pt">are </span><span style="font-family:'Times New Roman'; font-size:11pt">be susceptible to vCJD infection </span><span style="font-family:'Times New Roman'; font-size:11pt">(2,8,17,</span><span style="font-family:'Times New Roman'; font-size:11pt">22</span><span style="font-family:'Times New Roman'; font-size:11pt">) </span><span style="font-family:'Times New Roman'; font-size:11pt">and  as this polymorphism is known to influence the incubation period of other acquired human prion diseases, e.g. kuru</span><span style="font-family:'Times New Roman'; font-size:11pt"> (6</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt">19</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">, it is possible that vCJD cases may yet emerge in these genotypes in the future.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Table 1</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 genotypes in the UK population and in sCJD and vCJD</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 genotype</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">MM</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">MV</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">VV</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Normal Population</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">3</span><span style="font-family:'Times New Roman'; font-size:11pt">9</span><span style="font-family:'Times New Roman'; font-size:11pt">%</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">50%</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">1</span><span style="font-family:'Times New Roman'; font-size:11pt">1</span><span style="font-family:'Times New Roman'; font-size:11pt">%</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Sporadic CJD</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">61</span><span style="font-family:'Times New Roman'; font-size:11pt">%</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">20</span><span style="font-family:'Times New Roman'; font-size:11pt">%</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">1</span><span style="font-family:'Times New Roman'; font-size:11pt">9</span><span style="font-family:'Times New Roman'; font-size:11pt">%</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Variant CJD</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">100%</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt"> 0 (1,2)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">    0 (2)</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">(1) </span><span style="font-family:'Times New Roman'; font-size:11pt">A</span><span style="font-family:'Times New Roman'; font-size:11pt"> possible case of vCJD (not confirmed pathologically) has been reported in UK in a MV patient</span><span style="font-family:'Times New Roman'; font-size:11pt"> (18)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">(2) </span><span style="font-family:'Times New Roman'; font-size:11pt">E</span><span style="font-family:'Times New Roman'; font-size:11pt">vidence for asymptomatic vCJD infection in these genotypes</span><span style="font-family:'Times New Roman'; font-size:11pt"> (8,17,</span><span style="font-family:'Times New Roman'; font-size:11pt">22</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We studied the tissue distribution </span><span style="font-family:'Times New Roman'; font-size:11pt">in the body </span><span style="font-family:'Times New Roman'; font-size:11pt">of the abnormal prion protein in vCJD, and found that in addition to accumulating in the central nervous sy</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">tem (CNS), it was widely distributed in lymphoid tissues throughout the body, including the spleen, lymph nodes, tonsil</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt">Peyer’s patches in the gut</span><span style="font-family:'Times New Roman'; font-size:11pt"> (10)</span><span style="font-family:'Times New Roman'; font-size:11pt">. In collaboration with colleagues we </span><span style="font-family:'Times New Roman'; font-size:11pt">later</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">confirmed </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> infectivity in these tissues, with lower levels present in lymphoid tissues than in the CNS</span><span style="font-family:'Times New Roman'; font-size:11pt"> (4)</span><span style="font-family:'Times New Roman'; font-size:11pt">. In anoth</span><span style="font-family:'Times New Roman'; font-size:11pt">er collaborative study we </span><span style="font-family:'Times New Roman'; font-size:11pt">demonstrated evidence that blood (packed red blood cells) transfused from individuals who subsequently died from vCJD was infectious</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">had </span><span style="font-family:'Times New Roman'; font-size:11pt">transmitted vCJD infection on four occasions</span><span style="font-family:'Times New Roman'; font-size:11pt"> (12,</span><span style="font-family:'Times New Roman'; font-size:11pt">22</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">. Since then much research has been carried out to develop a blood test for vCJD,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and although one test has shown promise in patients with the signs and symptoms of vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> (7)</span><span style="font-family:'Times New Roman'; font-size:11pt">, it is not yet known if </span><span style="font-family:'Times New Roman'; font-size:11pt">preclinical vCJD </span><span style="font-family:'Times New Roman'; font-size:11pt">infections can be detected. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">In collaboration with colleagues, we identified </span><span style="font-family:'Times New Roman'; font-size:11pt">appendix</span><span style="font-family:'Times New Roman'; font-size:11pt"> tissue s</span><span style="font-family:'Times New Roman'; font-size:11pt">amples</span><span style="font-family:'Times New Roman'; font-size:11pt"> that had been removed from some individuals who subsequently developed and died from vCJD, and found that the abnormal prion protein coul</span><span style="font-family:'Times New Roman'; font-size:11pt">d accumulate in lymphoid follicles in the appendix</span><span style="font-family:'Times New Roman'; font-size:11pt"> before the onset of symptoms of vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> (13,14)</span><span style="font-family:'Times New Roman'; font-size:11pt">. This finding l</span><span style="font-family:'Times New Roman'; font-size:11pt">ead to the hypothesis that the prevalence</span><span style="font-family:'Times New Roman'; font-size:11pt"> of vCJD infection in the UK could be estim</span><span style="font-family:'Times New Roman'; font-size:11pt">ated by studying lymphoid follicle</span><span style="font-family:'Times New Roman'; font-size:11pt">s (</span><span style="font-family:'Times New Roman'; font-size:11pt"> in </span><span style="font-family:'Times New Roman'; font-size:11pt">tonsil</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt">appendix </span><span style="font-family:'Times New Roman'; font-size:11pt">samples</span><span style="font-family:'Times New Roman'; font-size:11pt"> removed from individuals in the UK population </span><span style="font-family:'Times New Roman'; font-size:11pt">with</span><span style="font-family:'Times New Roman'; font-size:11pt"> no signs or symptoms of vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> to detect the presence of the disease-associated prion protein, which accumulates in these tissues in vCJD, but not in other forms of CJD</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">I have been involved in 2 major </span><span style="font-family:'Times New Roman'; font-size:11pt">studies on the tissue-based prevalence of vCJD in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> (8,15) </span><span style="font-family:'Times New Roman'; font-size:11pt">the most recent of which estimates that around 1 in 2,000 individual</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the UK may be infected with the prion that causes vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Response</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">s</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> to questions</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> posed:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What do you consider to be the likely prevalence of subclinical vCJD infection in the UK population? What evidence is there to support this view?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">It is difficult to measure the precise prevalence of </span><span style="font-family:'Times New Roman'; font-size:11pt">subclinical</span><span style="font-family:'Times New Roman'; font-size:11pt"> vCJD infection in the UK population, since there is no validated screening test (e.g. a blood test) of high specificity and sensitivity for asymptomatic vCJD infection. The only estimates of  subclinical vCJD prevalence have been derived from tissue-based studies, where </span><span style="font-family:'Times New Roman'; font-size:11pt">formalin-fixed </span><span style="font-family:'Times New Roman'; font-size:11pt">paraffin-embedded blocks of appendix and/or tonsil specimens from NHS Histopathology Department archives have been screened in large numbers to demonstrate the presence of disease-associated prion protein by immunohistochemistry</span><span style="font-family:'Times New Roman'; font-size:11pt"> (8,15)</span><span style="font-family:'Times New Roman'; font-size:11pt">. These tissues contain lymphoid follicles with follicular dendritic cells, which appear to support prion replication in vCJD. Immunohistochemistry has identified the accumulation</span><span style="font-family:'Times New Roman'; font-size:11pt"> of disease-assoc</span><span style="font-family:'Times New Roman'; font-size:11pt">i</span><span style="font-family:'Times New Roman'; font-size:11pt">at</span><span style="font-family:'Times New Roman'; font-size:11pt">ed prion </span><span style="font-family:'Times New Roman'; font-size:11pt">protein </span><span style="font-family:'Times New Roman'; font-size:11pt">in a small number of appendi</span><span style="font-family:'Times New Roman'; font-size:11pt">x</span><span style="font-family:'Times New Roman'; font-size:11pt"> samples removed before the onset of neurological illness in individual</span><span style="font-family:'Times New Roman'; font-size:11pt">s who later died</span><span style="font-family:'Times New Roman'; font-size:11pt"> from vCJD. Th</span><span style="font-family:'Times New Roman'; font-size:11pt">is method</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">has not </span><span style="font-family:'Times New Roman'; font-size:11pt">detected disease-associated prion protein </span><span style="font-family:'Times New Roman'; font-size:11pt">in these tissues in </span><span style="font-family:'Times New Roman'; font-size:11pt">patients with </span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">CJD.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Two major</span><span style="font-family:'Times New Roman'; font-size:11pt"> studies using </span><span style="font-family:'Times New Roman'; font-size:11pt">a tissue-based</span><span style="font-family:'Times New Roman'; font-size:11pt"> approach have been reported in UK, </span><span style="font-family:'Times New Roman'; font-size:11pt">both</span><span style="font-family:'Times New Roman'; font-size:11pt"> of which were given research ethics approval requiring the use of anonymised samples from patient</span><span style="font-family:'Times New Roman'; font-size:11pt">s of known birth cohorts</span><span style="font-family:'Times New Roman'; font-size:11pt"> (8,</span><span style="font-family:'Times New Roman'; font-size:11pt">15)</span><span style="font-family:'Times New Roman'; font-size:11pt">. In 200</span><span style="font-family:'Times New Roman'; font-size:11pt">4, my colleagues and I reported a study </span><span style="font-family:'Times New Roman'; font-size:11pt">funded by DH </span><span style="font-family:'Times New Roman'; font-size:11pt">of over 12,500 tonsil and appendix samples: 11,109 were appendix samples, 3 of which were positive and were obtained from patients aged 20-29 years of age when operated on in 1996-99</span><span style="font-family:'Times New Roman'; font-size:11pt"> (15)</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt"> Experimental transmission was attempted on material from one of the positive samples, which was unsuccessful</span><span style="font-family:'Times New Roman'; font-size:11pt"> (2</span><span style="font-family:'Times New Roman'; font-size:11pt">6</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 analysis was performed on </span><span style="font-family:'Times New Roman'; font-size:11pt">DNA extracted from </span><span style="font-family:'Times New Roman'; font-size:11pt">the other 2 positive </span><span style="font-family:'Times New Roman'; font-size:11pt">samples, showing both cases to be VV</span><span style="font-family:'Times New Roman'; font-size:11pt"> (17)</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">The estimated prevalence of vCJD infection from this study was higher than the number of vCJD cases would have indicated: around 1 in 4000 of the UK population</span><span style="font-family:'Times New Roman'; font-size:11pt">, with wide confidence intervals</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Further research was </span><span style="font-family:'Times New Roman'; font-size:11pt">required to confirm this finding, and DH funded a larger </span><span style="font-family:'Times New Roman'; font-size:11pt">immunohistochemical study to detect disease-associated prion protein in UK appendix samples, including data on </span><span style="font-family:'Times New Roman'; font-size:11pt">birth cohort</span><span style="font-family:'Times New Roman'; font-size:11pt">, gender and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 genotype for each individual in the study. This was recently reported in the British Medical Journal</span><span style="font-family:'Times New Roman'; font-size:11pt"> (8)</span><span style="font-family:'Times New Roman'; font-size:11pt">; </span><span style="font-family:'Times New Roman'; font-size:11pt">16/32441 </span><span style="font-family:'Times New Roman'; font-size:11pt">cases were positive, of which 6 were </span><span style="font-family:'Times New Roman'; font-size:11pt">in the 1941-60 birth cohort and 10 in the 1961-85 birth cohort. </span><span style="font-family:'Times New Roman'; font-size:11pt">10 cases were males and 6 females; </span><span style="font-family:'Times New Roman'; font-size:11pt">8 cases were MM at </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129, 4 were MV and 4 VV.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">These findings give an estimated prevalence of vCJD infection in the UK population of 1 in 2000, with wide confidence intervals. The results of the 2004 and the 2013 studies are </span><span style="font-family:'Times New Roman'; font-size:11pt">consistent with each other</span><span style="font-family:'Times New Roman'; font-size:11pt">, particularly in view of the wide confidence intervals in both studies.</span><span style="font-family:'Times New Roman'; font-size:11pt"> The estimates from the more recent study are, however, more precise.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">On the basis of these findings, </span><span style="font-family:'Times New Roman'; font-size:11pt">I consider it </span><span style="font-family:'Times New Roman'; font-size:11pt">no</span><span style="font-family:'Times New Roman'; font-size:11pt">t</span><span style="font-family:'Times New Roman'; font-size:11pt"> unreasonable to conclude that the prevalence of subclinical vCJD infection in the UK </span><span style="font-family:'Times New Roman'; font-size:11pt">may be</span><span style="font-family:'Times New Roman'; font-size:11pt"> around 1</span><span style="font-family:'Times New Roman'; font-size:11pt"> in</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2,000 of the population</span><span style="font-family:'Times New Roman'; font-size:11pt"> and that all genetic subgroups are susceptible</span><span style="font-family:'Times New Roman'; font-size:11pt">. However, </span><span style="font-family:'Times New Roman'; font-size:11pt">some</span><span style="font-family:'Times New Roman'; font-size:11pt"> caveats have to be</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">taken into account:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">i</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">The positive results </span><span style="font-family:'Times New Roman'; font-size:11pt">reported </span><span style="font-family:'Times New Roman'; font-size:11pt">might be </span><span style="font-family:'Times New Roman'; font-size:11pt">false positives, either due to </span><span style="font-family:'Times New Roman'; font-size:11pt">non-specific </span><span style="font-family:'Times New Roman'; font-size:11pt">staining,</span><span style="font-family:'Times New Roman'; font-size:11pt"> or </span><span style="font-family:'Times New Roman'; font-size:11pt">positivity due to </span><span style="font-family:'Times New Roman'; font-size:11pt">other human prion diseases e.g. sCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">. The question of non-specific staining is being addressed in an on</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">going DH-funded study of appendixes removed from the 1970s and earlier – before BSE is thought to have entered the human food chain. Immunohistochemistry has not detected accumulation of disease-associated prion protein in sections of appendixes, tonsils and spleens from individuals who have died from sCJD, although one report exists of very low levels of disease-associated prion protein detected in unfixed samples of the spleen in a subgroup of sCJD patients by Western blot assay, a method considered to have a greater sensitivity</span><span style="font-family:'Times New Roman'; font-size:11pt"> (9)</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ii</span><span style="font-family:'Times New Roman'; font-size:11pt">. The positive results</span><span style="font-family:'Times New Roman'; font-size:11pt"> reported, if true positives, might give an underestimate</span><span style="font-family:'Times New Roman'; font-size:11pt"> of the prevalence of vCJD infection in the UK population, since immunohistochemistry is </span><span style="font-family:'Times New Roman'; font-size:11pt">perhaps </span><span style="font-family:'Times New Roman'; font-size:11pt">not as sensitive as other assays, e.g. Western blot, for the detection of disease-associated prion protein in tissues. However, Western blot assays require unfixed tissues, and all the samples in UK Histopathology Department archives are formalin-fixed paraffin-embedded tissues.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2. How might this subclinical infection rate translate to future cases of vCJD? What are the key uncertainties in the relationship between clinical and subclinical vCJD?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">I am uncertain as to how this estimated subclinical infection rate might translate to future cases of vCJD. All confirmed cases of vCJD so far belong to the</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 MM genetic subgroup. </span><span style="font-family:'Times New Roman'; font-size:11pt">A possible case of vCJD has been reported in the UK in a MV patient (18)</span><span style="font-family:'Times New Roman'; font-size:11pt">, but this case did not undergo autopsy and did not fulfil the criteria for a probable case of vCJD.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">It is reasonable to assume that at least some of the MM cases identified in the recent appendix survey by Gill et al (</span><span style="font-family:'Times New Roman'; font-size:11pt">8</span><span style="font-family:'Times New Roman'; font-size:11pt">) might go on to develop vCJD, but the same conclusion cannot be reached for the MV and VV groups. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We have published evidence to suggest that a MV individual became infected with vCJD as the result of a transfusion with packed red blood cells from a donor who later went on to die from vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> (22</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">. The recipient</span><span style="font-family:'Times New Roman'; font-size:11pt"> died from an unrelated cause 5 years after the transfusi</span><span style="font-family:'Times New Roman'; font-size:11pt">on, but did not develop vCJD prior to death</span><span style="font-family:'Times New Roman'; font-size:11pt">. Examination of brain and spinal cord samples from the post-mortem examination showed no evidence of vCJD prion infection, but the disease-associated prion was detected in the spleen and lymph nodes by immunohistochemistry and also in the spleen by Western blot assay.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The presence of vCJD infectivity in the spleen was subsequently confirmed by experimental transmission</span><span style="font-family:'Times New Roman'; font-size:11pt"> (1)</span><span style="font-family:'Times New Roman'; font-size:11pt">. This informative case demonstrates several key points:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1</span><span style="font-family:'Times New Roman'; font-size:11pt">. vCJD prions (transmitted in this case by blood transfusion) can infect individuals of the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 MV genotype</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2</span><span style="font-family:'Times New Roman'; font-size:11pt">. vCJD infection can result in a subclinical infection for at least 5 years, during which </span><span style="font-family:'Times New Roman'; font-size:11pt">time </span><span style="font-family:'Times New Roman'; font-size:11pt">the lymphoid tissues in the body </span><span style="font-family:'Times New Roman'; font-size:11pt">are likely to be</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">infectious</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Individuals with subclinical vCJD may therefore be capable of spreading vCJD infectivity to other by blood transfusion or though surgical instruments used on lymphoid tissues, </span><span style="font-family:'Times New Roman'; font-size:11pt">e.g.</span><span style="font-family:'Times New Roman'; font-size:11pt"> tonsil, spleen, appendix.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">4</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Positive immunohistochemistry for disease-associated prion protein in lymphoid tissues can be a true marker of prion infectivity</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">5</span><span style="font-family:'Times New Roman'; font-size:11pt">. vCJD infection in an </span><span style="font-family:'Times New Roman'; font-size:11pt">individual of the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 MV genotype retains its biochemical profile on Western blot assay.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Studies of kuru, an extinct disease identified in the 1950s in Papua New Guinea, showed that the disease was spread by from person to person due to dietary practices in certain remote tribes, and became an important cause of death, particularly in women and children. The incubation period for Kuru was influenced by the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP </span><span style="font-family:'Times New Roman'; font-size:11pt">codon 129 genotype, with the shortest incubation periods in the MM genotype and longer periods in the other genotypes particularly in the MV genotype, where incubation periods of over 40 years were identified</span><span style="font-family:'Times New Roman'; font-size:11pt"> (6,</span><span style="font-family:'Times New Roman'; font-size:11pt">19)</span><span style="font-family:'Times New Roman'; font-size:11pt">. The effect </span><span style="font-family:'Times New Roman'; font-size:11pt">of the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 genotype o</span><span style="font-family:'Times New Roman'; font-size:11pt">n incubation periods may depend on the stain of the infectious prion, as in </span><span style="font-family:'Times New Roman'; font-size:11pt">iatrogenic CJD occurring as a consequence of treatment with </span><span style="font-family:'Times New Roman'; font-size:11pt">human growth hormone in </span><span style="font-family:'Times New Roman'; font-size:11pt">the USA, </span><span style="font-family:'Times New Roman'; font-size:11pt">France and the UK. </span><span style="font-family:'Times New Roman'; font-size:11pt">The first of these cases in the UK was reported in 1985</span><span style="font-family:'Times New Roman'; font-size:11pt"> (24</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt">25</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">, since when there have been over 60 cases (5 in 2012 and 1 so far in 2013), with incubation periods of over 30 years in some individuals. These</span><span style="font-family:'Times New Roman'; font-size:11pt"> observations suggest that differences in </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 genotype</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> may result in very prolonged incubation periods</span><span style="font-family:'Times New Roman'; font-size:11pt"> for vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">, during which the infected individuals may represent a source of secondary infection to others in the population. Infected individuals may die of other causes before they develop signs and symptoms of prion infection. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The key uncertainties in the relationship between clinical and subclinical vCJD are:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1</span><span style="font-family:'Times New Roman'; font-size:11pt">. The influence of the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 genotype on the emergence of clinical disease – will clinical vCJD only occur in the MM genotype</span><span style="font-family:'Times New Roman'; font-size:11pt">, while other genotypes may become </span><span style="font-family:'Times New Roman'; font-size:11pt">infected, but never develop disease</span><span style="font-family:'Times New Roman'; font-size:11pt">?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2</span><span style="font-family:'Times New Roman'; font-size:11pt">. The effect of the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 genotype on </span><span style="font-family:'Times New Roman'; font-size:11pt">disease </span><span style="font-family:'Times New Roman'; font-size:11pt">incubation periods, which can extend to several decades.</span><span style="font-family:'Times New Roman'; font-size:11pt"> There have been very few cases of clinical vCJD in t</span><span style="font-family:'Times New Roman'; font-size:11pt">he elderly</span><span style="font-family:'Times New Roman'; font-size:11pt"> and it is unclear if the diagnosis in this age group is</span><span style="font-family:'Times New Roman'; font-size:11pt"> complicated by the occurrence of commoner neurodegenerative diseases in this age group, particularly Alzheimer’s disease. Further work to determine more precisely the </span><span style="font-family:'Times New Roman'; font-size:11pt">prevalence of clinical vCJD in this population group would help understand more about disease incubation periods and the effects of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 genotype, </span><span style="font-family:'Times New Roman'; font-size:11pt">particularly in view of the recent finding of apparent subclinical vCJD in 6 cases in the 1941-60 birth cohort in the appendix study by Gill et al (8).</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3</span><span style="font-family:'Times New Roman'; font-size:11pt">. C</span><span style="font-family:'Times New Roman'; font-size:11pt">linical vCJD in </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 VV and MV </span><span style="font-family:'Times New Roman'; font-size:11pt">genotypes might differ in its clinicopathological features from </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD </span><span style="font-family:'Times New Roman'; font-size:11pt">in the MM genotype, although the biochemical profile of the vCJD prion may be preserved, as in the spleen of the </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> infection in the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 MV individual described above</span><span style="font-family:'Times New Roman'; font-size:11pt"> (1,</span><span style="font-family:'Times New Roman'; font-size:11pt">22</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4</span><span style="font-family:'Times New Roman'; font-size:11pt">. It is therefore conceivable that subclinical vCJD infection in </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 VV and MV genotypes could be transmitted to individuals of the</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 MM genotype, resulting in clinical vCJD.</span><span style="font-family:'Times New Roman'; font-size:11pt"> We do not know the identity of those individuals identified as being positive for disease-associated prion protein in the appendix studies</span><span style="font-family:'Times New Roman'; font-size:11pt"> (8,15)</span><span style="font-family:'Times New Roman'; font-size:11pt">, but it is conceivable that some of this group may have donated blood or undergone surgery.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3. What are the likely routes of infection for vCJD? How have the potential modes of transmission changed over time?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">There is strong evidence to indicate that vCJD results from human infection with the BSE agent</span><span style="font-family:'Times New Roman'; font-size:11pt"> (3,5)</span><span style="font-family:'Times New Roman'; font-size:11pt">. The most likely route of this infection is dietary exposure through the consumption of BSE-infected meat products. Other potential sources of primary BSE infection have been considered, e.g. occupational (farmers, veterinarians, abattoir workers) and medicines or vaccines prepared using bovine components, but no evidence exists to support these possibilities</span><span style="font-family:'Times New Roman'; font-size:11pt"> (27</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">There is also evidence that secondary vCJD transmission can occur from person to person by the transfusion of non-leucodepleted red blood cells</span><span style="font-family:'Times New Roman'; font-size:11pt"> (12,</span><span style="font-family:'Times New Roman'; font-size:11pt">2</span><span style="font-family:'Times New Roman'; font-size:11pt">2</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">, and by the administration of large volumes of UK-derived plasma products</span><span style="font-family:'Times New Roman'; font-size:11pt"> (</span><span style="font-family:'Times New Roman'; font-size:11pt">2</span><span style="font-family:'Times New Roman'; font-size:11pt">3</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">. Other possible sources of secondary vCJD transmission include t</span><span style="font-family:'Times New Roman'; font-size:11pt">he reuse of surgical instruments </span><span style="font-family:'Times New Roman'; font-size:11pt">previously used in surgery on the CNS and lymphoid tissues in a patient with subclinical vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">, when the instruments might harbour enough infectivity to cause transmission</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Prions bind to metal surfaces, and inactivation of prion infectivity is difficult to achieve</span><span style="font-family:'Times New Roman'; font-size:11pt"> (29</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">There is no epidemiolo</span><span style="font-family:'Times New Roman'; font-size:11pt">gical evidence to indicate that </span><span style="font-family:'Times New Roman'; font-size:11pt">transmission of vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">by surgery (including dental surgery) </span><span style="font-family:'Times New Roman'; font-size:11pt">has occurred to date</span><span style="font-family:'Times New Roman'; font-size:11pt"> (27)</span><span style="font-family:'Times New Roman'; font-size:11pt">, although the identificati</span><span style="font-family:'Times New Roman'; font-size:11pt">on of such instances</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">is likely to be difficult. </span><span style="font-family:'Times New Roman'; font-size:11pt">No evidence of </span><span style="font-family:'Times New Roman'; font-size:11pt">vertical (</span><span style="font-family:'Times New Roman'; font-size:11pt">maternal</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> transmission of vCJD has occurred so far in children born to mothers who had clinical vCJD during pregnancy</span><span style="font-family:'Times New Roman'; font-size:11pt"> (20)</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The potential modes of transmission of vCJD have changed over time, particularly since 1996, when reinforced measures were introduced to control the entry of BSE-infected meat into the human food chain in the UK. The incidence of BSE has declined significantly since 1996, although occasional cases have been identified in cattle born after the reinforced animal food ban, for reasons that are still unclear</span><span style="font-family:'Times New Roman'; font-size:11pt"> (21)</span><span style="font-family:'Times New Roman'; font-size:11pt">. For these reasons, the dietary risk of primary infection with BSE is now very much lower in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> than previously</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Secondary transmission of vCJD by blood transfusion</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> organ/tissue transplantation,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the use of UK-derived plasma products</span><span style="font-family:'Times New Roman'; font-size:11pt"> or contaminated surgical instruments remains a possible risk, </span><span style="font-family:'Times New Roman'; font-size:11pt">and thousands of individuals in the UK have been identified and notified as being “at increased risk” of vCJD due to potential exposures by these routes, of which the largest single group is adult patients with haemophilia. These individuals are though</span><span style="font-family:'Times New Roman'; font-size:11pt">t</span><span style="font-family:'Times New Roman'; font-size:11pt"> to be at a sufficiently increased risk of vCJD that they in turn might transmit the infection to another person. Such individuals have to undergo “public health precautions” (see below) when accessing healthcare</span><span style="font-family:'Times New Roman'; font-size:11pt"> (</span><a href="http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/</span></a><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">CreutzfeldtJakobdisease</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">4. What procedures are currently in place to monitor, control and prevent further spread of vCJD across the UK population? What more could be done to reduce the risk posed by vCJD?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">NCJ</span><span style="font-family:'Times New Roman'; font-size:11pt">DRSU is funded by DH to monitor </span><span style="font-family:'Times New Roman'; font-size:11pt">all forms of human prion diseas</span><span style="font-family:'Times New Roman'; font-size:11pt">e across the UK, including vCJD:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Since 1996, after only the first 12 cases were identified, </span><span style="font-family:'Times New Roman'; font-size:11pt">“</span><span style="font-family:'Times New Roman'; font-size:11pt">r</span><span style="font-family:'Times New Roman'; font-size:11pt">eal – time” </span><span style="font-family:'Times New Roman'; font-size:11pt">report</span><span style="font-family:'Times New Roman'; font-size:11pt">ing </span><span style="font-family:'Times New Roman'; font-size:11pt">on the number of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD </span><span style="font-family:'Times New Roman'; font-size:11pt">cases, the clinical, pathological and genetic features of each case whenever possible (no</span><span style="font-family:'Times New Roman'; font-size:11pt">t all patients undergo autopsy), and studies </span><span style="font-family:'Times New Roman'; font-size:11pt">of </span><span style="font-family:'Times New Roman'; font-size:11pt">risk factors for </span><span style="font-family:'Times New Roman'; font-size:11pt">t</span><span style="font-family:'Times New Roman'; font-size:11pt">he development of th</span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt"> disease</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Identification of</span><span style="font-family:'Times New Roman'; font-size:11pt"> secondary vCJD transmission by blood transfusion and plasma products in collaboration with </span><span style="font-family:'Times New Roman'; font-size:11pt">the UK national blood authorities, enabling subsequent public health actions to be taken in terms of withdrawal of implicated products, contact tracing and notification</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3</span><span style="font-family:'Times New Roman'; font-size:11pt">. Close interactions with Public Health specialists across the UK to help identify and manage any potential incidents associated with surgical and occupational vCJD exposures. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">4</span><span style="font-family:'Times New Roman'; font-size:11pt">. Wide collaboration in enhanced surveillance </span><span style="font-family:'Times New Roman'; font-size:11pt">(including tissue-based surveillance) </span><span style="font-family:'Times New Roman'; font-size:11pt">for evidence of clinical or subclinical infection </span><span style="font-family:'Times New Roman'; font-size:11pt">in groups of patients designated as </span><span style="font-family:'Times New Roman'; font-size:11pt">being </span><span style="font-family:'Times New Roman'; font-size:11pt">at “increased risk” of vCJD.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">5</span><span style="font-family:'Times New Roman'; font-size:11pt">. Research in developing diagnostic tests and refining diagnostic criteria</span><span style="font-family:'Times New Roman'; font-size:11pt"> for vCJD.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">6</span><span style="font-family:'Times New Roman'; font-size:11pt">. Comparison o</span><span style="font-family:'Times New Roman'; font-size:11pt">f 177 UK vCJD cases with the 51</span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD cases that have occurred in 11 other countries.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">7</span><span style="font-family:'Times New Roman'; font-size:11pt">. Research into the properties of the vCJD agent, including its transmission characteristics in collaboration with other researchers.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">An effective </span><span style="font-family:'Times New Roman'; font-size:11pt">UK </span><span style="font-family:'Times New Roman'; font-size:11pt">surveillance system is absolutely critical to monitor the incidence and features of all forms of </span><span style="font-family:'Times New Roman'; font-size:11pt">human prion diseases, including vCJD. NCJDRSU identified vCJD at an early stage in the emergence of this new disease, and the current surveillance methodology will allow the early identification of any change in the prevalence of clinical vCJD. The combined clinical, pathological and epidemiological approach used by NCJDRSU will </span><span style="font-family:'Times New Roman'; font-size:11pt">aid</span><span style="font-family:'Times New Roman'; font-size:11pt"> the early identification of any new forms of human prion disease, e.g. vCJD in </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">PRNP</span><span style="font-family:'Times New Roman'; font-size:11pt"> codon 129 VV and MV genotypes. The close links established between</span><span style="font-family:'Times New Roman'; font-size:11pt"> NCJDRSU and </span><span style="font-family:'Times New Roman'; font-size:11pt">Public Health/</span><span style="font-family:'Times New Roman'; font-size:11pt">Health Protection Agencies and Blood Transfusion</span><span style="font-family:'Times New Roman'; font-size:11pt">/Transplant</span><span style="font-family:'Times New Roman'; font-size:11pt"> Authorities in the UK </span><span style="font-family:'Times New Roman'; font-size:11pt">allows </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">early identification, monitoring and management of any incidents with the potential for transmission of vCJD in a healthcare setting. </span><span style="font-family:'Times New Roman'; font-size:11pt">NCJDRSU has submitted a project outline to DH to address the questions over the prevalence of clinical vCJD in the elderly.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">A number of </span><span style="font-family:'Times New Roman'; font-size:11pt">population </span><span style="font-family:'Times New Roman'; font-size:11pt">measures have been introduced in the UK to control and </span><span style="font-family:'Times New Roman'; font-size:11pt">prevent the further spread of vCJD acr</span><span style="font-family:'Times New Roman'; font-size:11pt">oss the UK population; these have been</span><span style="font-family:'Times New Roman'; font-size:11pt"> based on risk assessment and risk management advice from a range of bodies including </span><span style="font-family:'Times New Roman'; font-size:11pt">the World Health Organisation, </span><span style="font-family:'Times New Roman'; font-size:11pt">DH, the Advisory Committee on the Safety of Blood, Tissues and Organs, the Advisory Committee for Dangerous Pathogens </span><span style="font-family:'Times New Roman'; font-size:11pt">(ACDP) and the ACDP Transmissible Spongiform Encephalopathy </span><span style="font-family:'Times New Roman'; font-size:11pt">Subgroup, the National Institute for Health and Care Excellence</span><span style="font-family:'Times New Roman'; font-size:11pt"> (NICE)</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">Public Health</span><span style="font-family:'Times New Roman'; font-size:11pt"> England and now defunct bodies including the Spongifo</span><span style="font-family:'Times New Roman'; font-size:11pt">rm Encephalopathy Advisory Committee</span><span style="font-family:'Times New Roman'; font-size:11pt"> and the CJD Incidents Panel.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Measures currently in place to reduce the risk of vCJD transmission via blood</span><span style="font-family:'Times New Roman'; font-size:11pt"> (</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">www.gov.uk/government/news/measures-currently-in-place-in-the-uk-to-reduce-the-potential-risk-of-vCJD-transmission-via-blood</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> (April 2013)</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1997</span><span style="font-family:'Times New Roman'; font-size:11pt">: Blood components, plasma products or tissues from any individual who later develops clinical vCJD are withdrawn/recalled to prevent their use.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1998</span><span style="font-family:'Times New Roman'; font-size:11pt">. Recombinant clotting factors for the treatment of haemophilia provided to patients under the </span><span style="font-family:'Times New Roman'; font-size:11pt">age of 16, and since 2005 this wa</span><span style="font-family:'Times New Roman'; font-size:11pt">s extended to all patients for whom it is suitable.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1999</span><span style="font-family:'Times New Roman'; font-size:11pt">: Leucodepletion used in all blood for transfusion</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1999</span><span style="font-family:'Times New Roman'; font-size:11pt">: Plasma for the manufacture of fractionated plasma products is obtained from non-UK sources.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2004</span><span style="font-family:'Times New Roman'; font-size:11pt">: Individuals who received a transfusion of blood components since January 1980 are excluded from donating blood</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2004</span><span style="font-family:'Times New Roman'; font-size:11pt">: Exclusion criteria for blood donation were extended to previously transfused platelet donors and donors who are unsure if they have ever received a blood transfusion.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2004-5</span><span style="font-family:'Times New Roman'; font-size:11pt">: Fresh frozen plasma for treating babies and children born on or after 1</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:'Times New Roman'; font-size:11pt"> January 1996 is obtained from the USA.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2005</span><span style="font-family:'Times New Roman'; font-size:11pt">: Individuals who donated blood to recipients who later developed clinical vCJD and excluded from blood donation and the donation of tissues and organs for transplantation.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">In addition, efforts have been successful in promoting the appropriate use of blood in the NHS, especially in reducing the use of blood in surgery.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">The NICE guideline “Patient safety and reduction of risk of transmission of Creutzfeldt-Jakob disease (CJD) via interventional procedures</span><span style="font-family:'Times New Roman'; font-size:11pt">” was published in 2006, particularly addressing the risks of neurosurgical transmission of all forms of CJD.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3</span><span style="font-family:'Times New Roman'; font-size:11pt">. Decontamination standards in UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> hospitals and dental practices have been reviewed and guidelines established to ensure uniform high standards of the cleaning and decontamination of surgical instruments and endoscopes. DH has commissioned a </span><span style="font-family:'Times New Roman'; font-size:11pt">b</span><span style="font-family:'Times New Roman'; font-size:11pt">ody of research into </span><span style="font-family:'Times New Roman'; font-size:11pt">novel approaches to decontamination of prions.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">4</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Definite, probable or possible case of human prion disease, including vCJD and those identified as being at “increased risk” of vCJD are excluded from </span><span style="font-family:'Times New Roman'; font-size:11pt">blood, </span><span style="font-family:'Times New Roman'; font-size:11pt">organ and tissue donation.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">5</span><span style="font-family:'Times New Roman'; font-size:11pt">. The ACDP g</span><span style="font-family:'Times New Roman'; font-size:11pt">uidance </span><span style="font-family:'Times New Roman'; font-size:11pt">to “Minimise transmission risk of </span><span style="font-family:'Times New Roman'; font-size:11pt">CJD and vCJD in healthcare settings</span><span style="font-family:'Times New Roman'; font-size:11pt">” was first published in 2003 and subsequently updated (available at </span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group</span><span style="font-family:'Times New Roman'; font-size:11pt">). Further guidance is available to local public health/health protection teams</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">on the “</span><span style="font-family:'Times New Roman'; font-size:11pt">Public health actions to be taken following a report of a new case of CJD or a person at increased risk of CJD. Colindale (London)</span><span style="font-family:'Times New Roman'; font-size:11pt">” (a</span><span style="font-family:'Times New Roman'; font-size:11pt">vailable at</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span></p><p style="margin:0pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">h</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">ttp://www.hpa.org.uk/web/</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline"> HPAweb&amp;HPAwebStandard/HPAwebC/</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">1225960588712</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What more could be done to reduce the risk posed by vCJD?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Recommendations for further action:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Ensure that the consumption of animal proteins in ruminant and other feeds is banned. The re-emergence of BSE or another novel prion disease in cattle or other animals used for human food would be potentially disa</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">trous </span><span style="font-family:'Times New Roman'; font-size:11pt">in terms of increasing the risk of primary vCJD infections in UK.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Secure the </span><span style="font-family:'Times New Roman'; font-size:11pt">effective surveillance of vCJD and other human prion diseases</span><span style="font-family:'Times New Roman'; font-size:11pt"> by NCJDRSU </span><span style="font-family:'Times New Roman'; font-size:11pt">across all age groups </span><span style="font-family:'Times New Roman'; font-size:11pt">in the UK (current funding for NCJDRSU ends in March 2015).</span></li></ul><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Maintain current measures to reduce the risk of vCJD transmission in a healthcare setting and ensure a rapid review process is possible to introduce changes if required in response to any </span><span style="font-family:'Times New Roman'; font-size:11pt">future </span><span style="font-family:'Times New Roman'; font-size:11pt">changes in vCJD.</span></li></ul><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Promote collaborative research at an international level into the development of a blood test for vCJD (and other forms of CJD), and the development of </span><span style="font-family:'Times New Roman'; font-size:11pt">double blind controlled </span><span style="font-family:'Times New Roman'; font-size:11pt">clinical trials with </span><span style="font-family:'Times New Roman'; font-size:11pt">adequate</span><span style="font-family:'Times New Roman'; font-size:11pt"> numbers of patients.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">References</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1. </span><span style="font-family:'Times New Roman'; font-size:11pt">Bishop MT, Diack AB, Ritchie D</span><span style="font-family:'Times New Roman'; font-size:11pt">L, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Brain</span><span style="font-family:'Times New Roman'; font-size:11pt">. 2013;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">136</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">1139-45.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2. </span><span style="font-family:'Times New Roman'; font-size:11pt">Bishop MT, Hart P, Aitchison L, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet Neurol</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2006;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">5</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">393–8.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3. </span><span style="font-family:'Times New Roman'; font-size:11pt">Bruce ME, Will RG, Ironside JW, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Nature</span><span style="font-family:'Times New Roman'; font-size:11pt"> 1997;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">389</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">498–501.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4. </span><span style="font-family:'Times New Roman'; font-size:11pt">Bruce ME, McConnell I, Will RG, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2001;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">358</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">208–9.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5. </span><span style="font-family:'Times New Roman'; font-size:11pt">Collinge J, Sidle KCL, Meads J, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Nature</span><span style="font-family:'Times New Roman'; font-size:11pt"> 1996;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">383</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">685–90.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6. </span><span style="font-family:'Times New Roman'; font-size:11pt">Collinge J, Whitfield J, McKintosh E, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">P</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">hil Trans R Soc B</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2008;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">363</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">3725–39.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7. </span><span style="font-family:'Times New Roman'; font-size:11pt">Edgeworth JA, Farmer M, Sicilia A, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2011;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">377</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">487-93.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">8. </span><span style="font-family:'Times New Roman'; font-size:11pt">Gill O, Spencer Y, Richard-Loendt A, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">BMJ </span><span style="font-family:'Times New Roman'; font-size:11pt">2013;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">347</span><span style="font-family:'Times New Roman'; font-size:11pt">:f5675doi: 10.1136/bmj.f5675</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9. </span><span style="font-family:'Times New Roman'; font-size:11pt">Glatzel M, Abela E, Maissen M, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">N Engl J Med</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2003;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">349</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">1812–20.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">10. </span><span style="font-family:'Times New Roman'; font-size:11pt">Head MW, Ritchie D, Smith N, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Am J Pathol</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2004;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">164</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">143–53.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">11. </span><span style="font-family:'Times New Roman'; font-size:11pt">Heath CA, Cooper SA, Murray K, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Ann Neurol</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2010;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">67</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">761-70.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">12. </span><span style="font-family:'Times New Roman'; font-size:11pt">Hewitt PE, L</span><span style="font-family:'Times New Roman'; font-size:11pt">Lewelyn CA, Mackenzie J, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Vox Sang</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2006;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">91</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">221-30.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">13. </span><span style="font-family:'Times New Roman'; font-size:11pt">Hilton DA, Fathers E, Edwards P, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> 1998;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">352</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">703–4.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">14. </span><span style="font-family:'Times New Roman'; font-size:11pt">Hilton DA, </span><span style="font-family:'Times New Roman'; font-size:11pt">Ghani AC, Conyers L, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">BMJ </span><span style="font-family:'Times New Roman'; font-size:11pt">2002</span><span style="font-family:'Times New Roman'; font-size:11pt">;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">5</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">63</span><span style="font-family:'Times New Roman'; font-size:11pt">3–4.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">15. </span><span style="font-family:'Times New Roman'; font-size:11pt">Hilton DA, Ghani AC, Conyers L, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J Pathol</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2004; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">203</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">733–9.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">16. </span><span style="font-family:'Times New Roman'; font-size:11pt">Ironside JW, Head MW, Bell JE, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Histopathology</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2000;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">37</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">1–9.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">17. </span><span style="font-family:'Times New Roman'; font-size:11pt">Ironside JW, Bishop MT, Connolly K, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Br Med J</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2006;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">332</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">1186–8.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">18. </span><span style="font-family:'Times New Roman'; font-size:11pt">Kaski D, Mead S, Hyare H, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2009;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">374</span><span style="font-family:'Times New Roman'; font-size:11pt">:2128.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">19. </span><span style="font-family:'Times New Roman'; font-size:11pt">Lee HS, Brown P, Cervenakova L, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J Infect Dis</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2001;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">183</span><span style="font-family:'Times New Roman'; font-size:11pt">: 192–6.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">20. Murray K, Peters J, Stellitano L, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J Neurol Neurosurg Psychiatry</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2011;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">82</span><span style="font-family:'Times New Roman'; font-size:11pt">:729-31.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2</span><span style="font-family:'Times New Roman'; font-size:11pt">1</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Ortiz-Pelaez A, Stevenson MA, Wilesmith JW, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Vet Rec</span><span style="font-family:'Times New Roman'; font-size:11pt">. 2012;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">170</span><span style="font-family:'Times New Roman'; font-size:11pt">:389</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">22</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Peden AH, Head MW, Ritchie DL, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2004; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">364</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">477–9.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">23</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Peden A, McCardle L, Head MW, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Haemophilia</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2010;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">16</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">296-304.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">24</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Powell-Jackson J, Well RO, Kennedy P, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> 1985;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">244–6.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">25</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Swerdlow AJ, Higgins CD, Adlard P, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Neurology</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2003;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">61</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">783–91</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">26</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Wadsworth JD, Dalmau-Mena I, Joiner S, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J Pathol</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2011;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">223</span><span style="font-family:'Times New Roman'; font-size:11pt">:511-</span><span style="font-family:'Times New Roman'; font-size:11pt">8.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">27</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Ward HJT, Everington D, Cousens SN, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Ann Neurol</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2006;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">59</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">111–20.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">28</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Will RG, Ironside JW, Zeidler M, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> 1996;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">347</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt">921–5.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">29</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">World Health Organization. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">WHO infection control guidelines for transmissible spongiform encephalopathies</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><a href="http://who.int/csr/resources/publications/bse/whocdscsraph2003.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://who.int/csr/resources/publications/bse/whocdscsraph2003.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">30</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">World He</span><span style="font-family:'Times New Roman'; font-size:11pt">a</span><span style="font-family:'Times New Roman'; font-size:11pt">l</span><span style="font-family:'Times New Roman'; font-size:11pt">th O</span><span style="font-family:'Times New Roman'; font-size:11pt">rganisation. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">WHO manual for surveillance of human transmissible spongiform encephalopathies including variant Creutzfeldt-Jakob disease</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><a href="http://wholibdoc.who.int/publications/2003/924154588"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://wholibdoc.who.int/publications/2003/924154588</span></a></p><p style="margin:0pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt; text-align:justify"><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 18pt 0pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p></div></body></html>